Rapport Therapeutics Conference Call Summary Company Overview - **Company**: Rapport Therapeutics (NasdaqGM:RAPP) - **Focus**: Development of a novel drug for epilepsy treatment, specifically RAP-219, which is advancing from phase 2 to phase 3 trials [1][2] Core Points and Arguments Drug Mechanism and Efficacy - **Target**: RAP-219 is a TARP gamma-8 AMPA modulator, focusing on four brain structures to treat focal onset seizures and bipolar mania [3] - **Efficacy**: Preclinical models showed unprecedented efficacy in controlling seizures without significant adverse effects, unlike existing pan-AMPA antagonists [5][11] - **Clinical Data**: Phase 2 trial demonstrated a 78% median reduction in clinical seizures and a 72% reduction in electrographic seizures, surpassing initial expectations of 50% and 30% respectively [19][31] Safety Profile - **Tolerability**: The drug exhibited a low discontinuation rate of 10%, with all adverse events being mild to moderate, and no serious adverse events reported [21] - **Therapeutic Index**: The drug maintains a wide therapeutic index, which is crucial for its safety and efficacy [13] Trial Design and Execution - **Phase 3 Trial**: The design will include two parallel studies with approximately 330 subjects each, focusing on low-medium and mid-high dose strategies [24][25] - **Global Collaboration**: A partnership with Tenacia in China aims to enhance global development and patient enrollment for the phase 3 trials [27] Market Opportunity - **Target Population**: 30%-40% of the 1.8 million patients with focal onset seizures are refractory to current treatments, representing a significant market opportunity [30] - **Market Size**: The potential market for branded drugs in this segment is estimated at $15 billion [31] Additional Indications - **Bipolar Mania**: The drug is also being studied for bipolar mania, leveraging its mechanism to reduce glutamate transmission, which is implicated in the disorder [36][37] - **Tonic-Clonic Seizures**: Plans to initiate a phase 2 study for tonic-clonic seizures based on positive results from focal onset studies [39] Long-Acting Injectable Development - **Differentiation**: RAP-219 is being developed as a long-acting injectable (LAI), which is uncommon for anti-seizure medications. Its potency, low solubility, and long half-life make it suitable for this formulation [42][44] - **Market Impact**: The LAI could extend exclusivity and revenue durability, appealing to both patients and physicians [47] Conclusion - Rapport Therapeutics is positioned to make significant advancements in the treatment of epilepsy and bipolar disorder with its innovative drug RAP-219, backed by strong clinical data and a clear market strategy. The ongoing development of a long-acting injectable formulation further enhances its potential impact in the market [50]

Rapport Therapeutics FY Conference Summary Company Overview - **Company**: Rapport Therapeutics (NasdaqGM:RAPP) - **Industry**: Biotechnology, specifically focusing on neuroscience and epilepsy treatments Key Highlights from 2025 and Early 2026 - 2025 was a transformational year for Rapport, showcasing confirmatory data for their approach in precision neuroscience, particularly with their lead program RAP-219 targeting focal-onset seizures [3][4] - Proof-of-concept data released in September 2025 demonstrated a **72% reduction** in a novel biomarker and a **78% reduction** in clinical seizures in a refractory patient population [4][5] - A **24% seizure freedom rate** was also reported, allowing progression into registrational studies [5] Upcoming Clinical Trials - Phase 3 program for RAP-219 will be initiated in Q2 2026, accelerated from Q3 due to positive FDA interactions [5] - Two pivotal trials will be conducted in parallel, focusing on refractory focal-onset seizure patients, with three dose levels: low (0.25 mg), mid (0.75 mg), and high (1.25 mg) [6][7] Patient Population Insights - The proof-of-concept study enrolled patients with an RNS device, showing demographic similarities to those in traditional studies, but with a higher refractory rate [8][9] - 70% of enrolled patients were on 3-4 medications, indicating a highly refractory population [9] Efficacy and Safety Expectations - A clinically meaningful placebo-adjusted seizure reduction target is set at **30%-35%**, with a non-placebo adjusted target of **50%-55%** [10] - Emphasis on tolerability and ease of administration is crucial for market adoption, with a preference for once-daily dosing and minimal drug-drug interactions [11][12] Tolerability Profile - The phase 2 study reported only mild to moderate adverse events (AEs), with no severe AEs observed [14] - Anxiety was noted in some patients, but it was attributed to preexisting conditions rather than the drug itself [15][16] Market Opportunity - The market opportunity for RAP-219 in focal-onset seizures is estimated at **$2.5 billion**, based on a refractory population of 30%-40% of 1.8 million patients [18] - A long-acting injectable formulation is also in development, which could further enhance market potential [19] Long-Acting Injectable Insights - KOLs believe a long-acting injectable would be transformational for patients, addressing concerns about missed doses leading to breakthrough seizures [20][21] - The development of RAP-219 as a long-acting injectable is supported by its extended half-life and low solubility, making it suitable for this formulation [22][23] Enrollment and Trial Dynamics - Current trends show varying enrollment timelines for pivotal studies, with some taking 2-4 years [25] - Rapport aims to leverage excitement in the community and the completion of other ongoing trials to facilitate patient recruitment [26][27] Bipolar Mania Program - RAP-219 is also being explored for bipolar mania, with a focus on its potential to reduce excessive glutamate associated with the condition [28][29] - The primary endpoint for the bipolar mania trial is the Young Mania Rating Scale (YMRS), with a meaningful effect defined as a **4-point placebo-adjusted change** [35] Pain Program Focus - The company has shifted focus to a nicotinic acetylcholine receptor program for pain, which has shown promise in preclinical models [37][38] Financial Outlook - Rapport is funded into the second half of 2029, allowing for the completion of the phase 3 trial in focal-onset seizures and the phase 2 trial in bipolar mania [39] Strategic Positioning - The company is positioned to execute its programs independently, with no immediate plans for partnerships, although it remains open to opportunities that do not compromise its initiatives [42][43][44]

Rapport Therapeutics Conference Call Summary Company Overview - **Company**: Rapport Therapeutics (NasdaqGM:RAPP) - **Industry**: Precision Neuroscience - **Focus**: Development of therapies for neurological conditions using receptor-associated proteins Key Points and Arguments Company Vision and Strategy - Rapport Therapeutics aims to be a leading precision neuroscience company, leveraging receptor-associated proteins to create highly specific compounds for various neurological conditions [8][9] - The company was formed through a collaboration between Third Rock and Johnson & Johnson, bringing significant institutional knowledge to its programs [9] Lead Program: RAP-219 - **Description**: RAP-219 is a novel forebrain-restricted TARP gamma-8 AMPA modulator targeting focal onset seizures [10][11] - **Financial Position**: As of September 30, 2025, the company had approximately $513 million, providing a cash runway into the second half of 2029 [10] - **Clinical Progress**: Positive phase two data for RAP-219 was released in September 2025, with plans to enter pivotal studies in Q2 2026 [10][13] Market Opportunities - **Focal Onset Seizures**: Approximately 1.8 million patients in the U.S. with a market opportunity of $15 billion [16] - **Primary Generalized Tonic-Clonic Seizures**: Around 800,000 patients with a $7 billion market opportunity [16] - **Bipolar Mania**: 1.5 million patients with a $40 billion market opportunity [16] - **Long-Acting Injectable (LAI)**: Expected to be the first of its kind in epilepsy, providing significant revenue potential [15][16] Clinical Data and Efficacy - **Phase 2A Trial Results**: - 71% median reduction in long episodes (electrographic seizures) [27] - 77.8% reduction in clinical seizures, with 72% of patients achieving a 50% reduction [28] - 24% of patients achieved clinical seizure freedom, a significant outcome compared to historical placebo rates [29] - **Tolerability**: The drug was well tolerated with a low discontinuation rate of 10% [30] Future Developments - **Bipolar Mania Study**: Expected data in the first half of 2027 [35] - **Long-Acting Injectable**: Expected to enter IND-enabling studies with initial human PK data anticipated in 2027 [34][35] - **Discovery Pipeline**: Focused on nicotinic receptors with promising candidates for chronic pain and migraine [39] Regulatory and Market Positioning - Rapport Therapeutics has received positive feedback from the FDA, allowing for accelerated development of RAP-219 [13][32] - The company is positioned to potentially lead in the market with a new mechanism of action and favorable safety profile compared to existing treatments [44][46] Additional Important Information - The company emphasizes the importance of addressing treatment-resistant patients, with 30%-40% of focal onset seizure patients being refractory to current medications [16][18] - The long-acting injectable formulation is expected to mitigate risks associated with missed doses, a significant concern for patients and caregivers [47][48] - The discovery platform aims to create a self-sustaining pipeline, moving beyond single-asset dependency [38] This summary encapsulates the key insights from the conference call, highlighting the strategic direction, clinical advancements, and market potential of Rapport Therapeutics and its lead program, RAP-219.

Rapport Therapeutics Conference Call Summary Company Overview - Rapport Therapeutics is focused on precision neuroscience, leveraging receptor-associated proteins to enhance treatment efficacy and tolerability for patients [2][3] Key Programs - The lead program, RAP-219, is a TARP gamma-8 AMPA modulator, showing promising results in epilepsy and ongoing programs in bipolar mania [2][3] - RAP-219 has demonstrated a 78% median reduction in clinical seizure frequency and a 24% seizure freedom rate in a proof of concept study [11][12] FDA Engagement and Study Plans - The company plans to meet with the FDA by the end of 2025 for an end of phase two meeting, aiming to start phase three studies by Q3 2026 [4][5] - Two parallel registrational studies are planned, following a standard protocol for focal epilepsy [4][5] Safety and Efficacy Insights - The biological thesis focuses on modulating the AMPA receptor through TARP gamma-8, which is expressed in key brain structures related to focal seizures [6][8] - The tolerability profile from phase two data showed a 10% discontinuation rate, indicating best-in-class tolerability for anti-seizure medications [9] - Concerns regarding adverse events (AEs) related to psychiatric disorders were addressed, with no significant findings in their trials [10] Patient Population and Efficacy Expectations - The proof of concept study involved a highly refractory patient population, with 70% on three or four anti-seizure medications [16] - The efficacy results are expected to translate well into the broader phase three patient population, despite potential variability [18][13] Bipolar Mania and Other Indications - The company is exploring RAP-219 for bipolar mania, supported by the drug's mechanism targeting excitatory processes in the limbic structure [24][26] - Enrollment for the bipolar trial is progressing well, with data expected in 2027 [26] Market Opportunity - The potential market opportunity for RAP-219 in epilepsy is estimated to be multi-billion dollars, with expected utilization similar to existing treatments like Keppra [29] Upcoming Milestones - Key updates expected include the end of phase two meeting with the FDA, additional data analyses at AES in December 2025, and the initiation of phase three studies in 2026 [30][31] - The company has sufficient cash reserves, approximately $500 million, to fund operations through 2029 [32]